Terms: = Colorectal cancer AND SDHA, SDH2, 6389, ENSG00000073578, FP, P31040, SDHF AND Treatment
55 results:
1. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
Kinos S; Hagman H; Halonen P; Soveri LM; O'Reilly M; Pfeiffer P; Frödin JE; Sorbye H; Heervä E; Liposits G; Kallio R; Ålgars A; Ristamäki R; Salminen T; Bärlund M; Shah CH; McDermott R; Röckert R; Flygare P; Kwakman J; Teske A; Punt C; Glimelius B; Österlund P
Acta Oncol; 2024 May; 63():248-258. PubMed ID: 38698698
[TBL] [Abstract] [Full Text] [Related]
2. Fertility preservation in reproductive-aged female patients with colorectal cancer: a scoping review.
Landay SL; Burns JA; Bickle ML; Baltich Nelson B; Nipp RD
Support Care Cancer; 2023 Oct; 31(10):612. PubMed ID: 37796328
[TBL] [Abstract] [Full Text] [Related]
3. Real-World treatment Sequencing in Vulnerable Patients with Metastatic colorectal cancer: A Multicenter Retrospective Study.
Mitani S; Kito Y; Hino K; Kawakami K; Izawa N; Hanamura F; Yamamoto Y; Shoji H; Komori A; Boku S; Tsuchihashi K; Kato K; Nonagase Y; Matsumoto T; Furuta M; Kawakami H
Target Oncol; 2023 Sep; 18(5):707-715. PubMed ID: 37668815
[TBL] [Abstract] [Full Text] [Related]
4. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435
[TBL] [Abstract] [Full Text] [Related]
5. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Punt CJA; Heinemann V; Maughan T; Cremolini C; Van Cutsem E; McDermott R; Bodoky G; André T; Osterlund P; Teske AJ; Pfeiffer P
ESMO Open; 2023 Apr; 8(2):101199. PubMed ID: 37018874
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
Nan H; Guo P; Fan J; Zeng W; Hu C; Zheng C; Pan B; Cao Y; Ge Y; Xue X; Li W; Lin K
Front Immunol; 2023; 14():1093974. PubMed ID: 36949947
[TBL] [Abstract] [Full Text] [Related]
7. Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT).
Lombardi P; Aimar G; Peraldo-Neia C; Bonzano A; Depetris I; Fenocchio E; Filippi R; Quarà V; Milanesio M; Cavalloni G; Gammaitoni L; Basiricò M; Cagnazzo C; Ostano P; Chiorino G; Aglietta M; Leone F
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562382
[TBL] [Abstract] [Full Text] [Related]
8. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.
Chen S; Li X; Li Y; Yuan X; Geng C; Gao S; Li J; Ma B; Wang Z; Lu W; Hu HG
Theranostics; 2022; 12(15):6665-6681. PubMed ID: 36185610
[No Abstract] [Full Text] [Related]
9. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF
Tabernero J; Grothey A; Arnold D; de Gramont A; Ducreux M; O'Dwyer P; Tahiri A; Gilberg F; Irahara N; Schmoll HJ; Van Cutsem E
ESMO Open; 2022 Oct; 7(5):100559. PubMed ID: 36029653
[TBL] [Abstract] [Full Text] [Related]
10. A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis.
Roy S; Pan Z; Pal S
J Math Biol; 2022 Feb; 84(4):23. PubMed ID: 35212794
[TBL] [Abstract] [Full Text] [Related]
11. Post-induction Strategies in Metastatic colorectal cancer Patients Treated With First-Line Anti-EGFR-Based treatment: A Systematic Review and Meta-Analysis.
Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
[TBL] [Abstract] [Full Text] [Related]
12. Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Oneda E; Zaniboni A
Crit Rev Oncol Hematol; 2022 Jan; 169():103537. PubMed ID: 34801698
[TBL] [Abstract] [Full Text] [Related]
13. How I treat stage II colon cancer patients.
Taieb J; Karoui M; Basile D
ESMO Open; 2021 Aug; 6(4):100184. PubMed ID: 34237612
[TBL] [Abstract] [Full Text] [Related]
14. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population.
Min ST; Roohullah A; Tognela A; Jalali A; Lee M; Wong R; Shapiro J; Burge M; Yip D; Nott L; Zimet A; Lee B; Dean A; Steel S; Wong HL; Gibbs P; Lim SH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e56-e63. PubMed ID: 33870631
[TBL] [Abstract] [Full Text] [Related]
15. Fluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients.
Fouad MA; Salem SE; Osman AS; Badr DM; Hussein MM; Zekri AN; Hafez HF; Kamel MM; Shouman SA
Int J Immunopathol Pharmacol; 2021; 35():20587384211008332. PubMed ID: 33832346
[TBL] [Abstract] [Full Text] [Related]
16. Rectal cancer with complete endoscopic response after neoadjuvant therapy: what is the meaning of a positive MRI?
Gollub MJ; Das JP; Bates DDB; Fuqua JL; Golia Pernicka JS; Javed-Tayyab S; Paroder V; Petkovska I; Garcia-Aguilar J
Eur Radiol; 2021 Jul; 31(7):4731-4738. PubMed ID: 33449186
[TBL] [Abstract] [Full Text] [Related]
17. Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical colorectal cancer Models through Distinct Mechanistic and Pharmacologic Properties.
Gmeiner WH; Dominijanni A; Haber AO; Ghiraldeli LP; Caudell DL; D'Agostino R; Pasche BC; Smith TL; Deng Z; Kiren S; Mani C; Palle K; Brody JR
Mol Cancer Ther; 2021 Mar; 20(3):553-563. PubMed ID: 33361273
[TBL] [Abstract] [Full Text] [Related]
18. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic colorectal cancer: A Meta-Analysis.
Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
[TBL] [Abstract] [Full Text] [Related]
19. Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine.
Gmeiner WH
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751071
[TBL] [Abstract] [Full Text] [Related]
20. Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
Kurreck A; Heinemann V; Fischer von Weikersthal L; Decker T; Kaiser F; Uhlig J; Schenk M; Freiberg-Richter J; Peuser B; Denzlinger C; Graeven U; Schwaner I; Stahler A; Heinrich K; Jung A; Held S; von Einem JC; Stintzing S; Giessen-Jung C; Modest DP
Eur J Cancer; 2020 Sep; 137():81-92. PubMed ID: 32750502
[TBL] [Abstract] [Full Text] [Related]
[Next]
